2023
Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]
Lier A, Seval N, Vander Wyk B, Di Paola A, Springer S. Corrigendum to ‘Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder’ [J. Subst. Abuse Treat. vol. 142 (2022)/108852]. Journal Of Substance Use And Addiction Treatment 2023, 150: 209074. PMID: 37271717, DOI: 10.1016/j.josat.2023.209074.Peer-Reviewed Original Research
2022
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.Peer-Reviewed Original ResearchConceptsInjection opioid useOpioid use disorderHepatitis C virusOpioid useXR-NTXOpioid injectionUse disordersDouble-blind placebo-controlled trialExtended-release naltrexonePlacebo-controlled trialCopies/mLIntravenous opioid useTransmission of HIVJustice-involved populationsJustice-involved participantsInjection equipmentHigh treatment groupJustice-involved personsHCV antibodiesHIV RNAPlacebo groupTreat analysisC virusInjection useJustice-involved individuals